Antimicrobial resistance (AMR)

#Antibiotic resistance #Antimicrobial resistance (AMR) #Covid-19 #Drug discovery

AMR: why we need to advance the discovery of new antimicrobials

World Antimicrobial Awareness Week highlights the fact that antimicrobials have formed the bedrock of modern medicine, making surgeries, cancer care and treatments for life-threatening infections possible and improving human health in the process.  For years now, experts have laboured against the rise of antimicrobial resistance (AMR), urging governments to put… Read More

#Exclusive Content

World AMR Awareness Week logo
#ABPI #Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Association of the British Pharmaceutical Industry #UK

New antibiotics the only way to combat AMR, says ABPI 

Developing new antibiotics is essential to winning the fight against resistant infections, the Association of the British Pharmaceutical Industry (ABPI) has said.  The comments come ahead of World Antimicrobial Awareness Week (18-24 November), which aims to improve the awareness and understanding of antimicrobial resistance (AMR).   The… Read More

#News #Trending News

#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR)

Why the UK government’s antibiotics plans are irresponsible   

By DDW Editor Reece Armstrong  The threat of antimicrobial resistance (AMR) has long been a talking point for those invested in healthcare and life sciences. Indeed, for many, it is a looming threat for which inaction could result in very serious consequences for healthcare systems worldwide.   AMR is currently listed… Read More

#Exclusive Content #Opinion

Child with cystic fibrosis on ventilator
#Antimicrobial resistance (AMR) #Cystic fibrosis #Drug discovery

Partnership seeks to transform Cystic Fibrosis research

LifeArc, a national medical research charity, is joining the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate in a strategic partnership alongside Cystic Fibrosis Trust and Medicines Discovery Catapult (MDC). The CF AMR Syndicate aims to address unmet patient needs by linking people with CF with leading experts across industry, academia… Read More

#News

#Antimicrobial resistance (AMR) #Genetics / genomics #Genome sequencing #Pandemic

Q&A: Gene therapy opportunities from long-read sequencing 

Breakthroughs in gene therapy are only possible with an exact understanding of the genetic underpinnings of disease. To develop safe and effective gene therapies, researchers need confidence that genomic data is both complete and accurate. Here, DDW Editor Reece Armstrong speaks to Neil Ward, General Manager and VP at PacBio… Read More

#Exclusive Content

#Antimicrobial resistance (AMR) #Psychedelics #Sickle cell disorder (SCD)

This week in drug discovery (11-15 July)

News round-up by DDW’s Reece Armstrong for 11 – 15 July. Urgency a must for global fight against AMR, report says Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by… Read More

#News

#Antibiotics #Antimicrobial resistance (AMR) #Vaccines #WHO

Urgency a must for global fight against AMR, report says  

Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by the World Health Organisation (WHO).  WHO has released the first-ever report1 looking at the pipeline of vaccines currently in… Read More

#News #Trending News

#Antimicrobial resistance (AMR) #Cystic fibrosis

Destiny Pharma granted award from Cystic Fibrosis Foundation  

Biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation to help the company advance its lead compound for cystic fibrosis patients who have been infected with methicillin-resistant Staphylococcus aureus (MRSA).  Destiny Pharma will establish a research project with the Cystic Fibrosis Foundation where… Read More

#News

#Antimicrobial resistance (AMR) #Covid-19 #Immunology / Virology & Vaccines

This week in drug discovery (July 4-8)

A Covid-19 lawsuit, a heart attack treatment developed using spider venom and a collaboration to fight antimicrobial resistance (AMR) are some of the theme’s of this week’s news round-up.  News round-up by DDW’s Reece Armstrong for 4 – 8 July. CureVac lawsuit against BioNTech over Covid-19 vaccine technology Biopharmaceutical… Read More

#News

Bacteria
#Antimicrobial resistance (AMR) #Boehringer Ingelheim #Precision medicine

Joint venture launches to fight antimicrobial resistance  

A new joint-venture has been formed between Evotec, Boehringer Ingelheim and bioMérieux in a bid to fight antimicrobial resistance (AMR) through the development of new antimicrobials and diagnostics.  Aurobac Therapeutics SAS will combine the expertise of its three founding companies and utilise a precision approach in the… Read More

#News

Antibiotics
#Antibiotics #Antimicrobial resistance (AMR) #Preclinical development

Nosopharm brings antibiotic one step closer to clinical development

Biotechnology company Nosopharm has reported positive toxicology results for its first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. The company’s NOSO-502 is the first clinical candidate in the new class of antibiotics called Odilorhabdins and is being developed alongside GNA NOW, a European Consortium funded by the Innovative Medicines… Read More

#News

Antibiotics
#Antimicrobial resistance (AMR) #Antimicrobials #National Institute for Health and Care Excellence (NICE)

Important milestone reached in UK’s AMR fight 

The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of two new antimicrobial drugs to be used as part of a subscription style model within the healthcare system.   NICE has evaluated cefiderocol and ceftazidime–avibactam as part of a project with… Read More

#News